Comment: Local guidance is available from the Forth Valley Asthma Online Resource and COPD Guidance

Also see <u>British Guideline on the Management of Asthma</u> and <u>NICE guideline [NG115]</u> Chronic obstructive pulmonary <u>disease in over 16s: diagnosis and management</u>

In new patients, consideration should be given to prescribing formulary choice dry powder inhaler (DPI) devices rather than metered dose inhalers (MDI) in order to reduce the carbon footprint.

Inhaler devices which are carbon neutral or with a low carbon footprint are marked as For further information on how to reduce the carbon footprint on inhaler prescribing refer to <u>https://www.greenerpractice.co.uk/greener-practice-guide-to-inhaler-prescribing</u>

1 A	irways Disease, Obstructive	Primary Care	Acute/ Specialist Services
Antii	muscarinics (inhaled)	1	1
Long	-acting Antimuscarinic Monotherapy (LAMA)		
/	Incruse Ellipta [®] (Umeclidinium) (DPI) (1 st line) (licensed for use in those aged 18 years old and upwards)	4	✓
/	Spiriva Respimat [®] (Tiotropium) (Soft mist inhaler[SMI]) (2 nd line) (licensed for use in those aged 6 years old and upwards in asthma)	1	~
Shor	t-acting Antimuscarinic Monotherapy (SAMA)		
	Ipratropium nebules	1	✓
Coml	bination Inhalers	I	
Long	-acting Antimuscarinic and Long-acting Beta2-adrenoceptor agonist	inhaler (LAM	A + LABA)
/	Anoro Ellipta [®] (Umeclidinium + vilanterol) (DPI) (1 st line) (licensed for use in those aged 18 years old and upwards)	1	✓
1	Spiolto Respimat [®] (Tiotropium + olodaterol) (SMI) (2 nd line) (licensed for use in those aged 18 years old and upwards)	1	~
	Bevespi Aerosphere [®] (Glycopyrronium + formoterol) (MDI) (licensed for use in those aged 18 years old and upwards)	✓	×
Shor	t-acting Beta ₂ -adrenoceptor agonist + Short-acting Antimuscarinic (S	ABA + SAMA	A)
	Salbutamol + ipratropium nebules	✓	✓
Beta ₂	-adrenoceptor agonists		
Long	-acting		
	No formulary choice as monotherapy		
Shor	t-acting (SABA)		
/	Salbutamol (Easyhaler [®] salbutamol) (DPI) (licensed for use from age 4 years and upwards)	1	~
	Salbutamol (MDI)	✓	✓
	Salbutamol nebules	1	✓
carboi name	nent: Different brands of salbutamol MDI have different carbon footprints e.g. Sala in footprint than Ventolin Evohaler [®] . Consideration should be given to prescribing s (this will ensure a lower carbon footprint inhaler is dispensed by the Pharmacy), ir viewed and they consent to being prescribed a lower carbon footprint MDI.	albutamol MDI's	s by brand

Key ✓ Initiate and continue +Continue where appropriate.

	s using more than 6 SABA inhalers per annum should be reviewed to ensure app 's asthma.	propriate manage	ement of the
Cortic	osteroids (inhaled)		
	ent: See <u>HIS Steroid Emergency Card</u> for further info. regarding patients who are I crisis and should be provided with a steroid emergency card.	e considered at l	nigh risk of
Cortic	osteroid Monotherapy		
	Easyhaler [®] Beclomethasone (1 st line DPI)	1	~
	(licensed for use in those aged 18 years and upwards)		
	Easyhaler [®] Budesonide (2 nd line DPI)	1	✓
	(licensed for use in those aged 6 years and upwards)		
	Soprobec [®] (1 st line MDI) (Beclometasone Dipropionate)	✓	✓
	(200mcg, 250mcg strengths not licensed for use in children less than 12 years old)		
Comb	ination Inhalers		
Inhale	d Corticosteroid + Long-acting Beta ₂ -adrenoceptor agonist (ICS + L	ABA)	
Asthn	na		
	Fostair NEXThaler [®] 100/6, 200/6	✓	~
	(Beclometasone extra-fine + formoterol) (1 st line DPI)		
	(licensed for use in those aged 18 years old and upwards)		
	Relvar Ellipta [®] 92/22,184/22 (Fluticasone furoate + vilanterol) (1 st line DPI) (licensed for use in those aged 12 years old and upwards in asthma)	~	~
/	Fobumix Easyhaler [®] 80/4.5,160/4.5,320/9 (Budesonide + formoterol) (2 nd line DPI)	*	~
	ent: Not all strengths of Fobumix Easyhaler [®] are licensed for all ages. Fobumix E adolescents and children aged 6 years and older. Higher strengths are not suitable		
/	Luforbec [®] 100/6, 200/6 (Beclometasone extra-fine + formoterol) (1 st line MDI) (licensed for use in those aged 18 years old and upwards)	*	~
	Flutiform [®] (Fluticasone propionate + formoterol) (2 nd line (MDI)	✓	✓
	(50/5mcg inhaler licensed for use in those aged 5 years old and upwards, 125/5mcg inhaler licensed from 12 years old, 250/10mcg inhaler only licensed in adults)		
Comm	ent: Flutiform [®] has a high carbon footprint and should only be considered if alterr	native options ar	e unsuitable
	ent: Luforbec [®] MDI shelf life is 3 months after dispensing – prescribe appropriate assary wastage	e quantities to av	/oid
	Symbicort Turbohaler [®] 200 micrograms/6 micrograms/inhalation (Budesonide + Formoterol)	✓	✓
older) therapy	ent: Symbicort Turbohaler [®] is accepted for use as reliever therapy for adults and with mild asthma in patients who would otherwise receive low dose inhaled cort / plus short-acting beta-2 adrenoceptor agonist (SABA) as needed.		
COPE			
	Fostair NEXThaler [®] 100/6 (Beclometasone extra-fine + formoterol) (1 st line DPI) (licensed for use in those aged 18 years old and upwards)	*	~
	Relvar Ellipta [®] 92/22 (Fluticasone furoate + vilanterol) (1 st line DPI)	1	✓
	(licensed for use in those aged 18 years old and upwards)		

Key \checkmark Initiate and continue \oplus Continue where appropriate.

/	Fobumix Easyhaler [®] 160/4.5,320/9 (Budesonide + formoterol inhaler) (2 nd line DPI) (licensed for use in those aged 18 years old and upwards)	~	✓
/	Luforbec [®] 100/6 (Beclometasone extra-fine + formoterol) (1 st line MDI) (licensed for use in those aged 18 years old and upwards)	✓	*
	ed corticosteroid + Long-acting Beta₂-adrenoceptor agonist + Lor + LABA + LAMA)	ng-acting ant	imuscarinic
` Asth	-		
	Trimbow [®] 87/5/9mcg, 172/5/9mcg (Beclometasone + formoterol + glycopyrronium) (MDI) (licensed for use in those aged 18 years old and upwards)	*	~
СОР	D		
	Trelegy Ellipta [®] (Fluticasone furoate + vilanterol + umeclidinium) (DPI) (licensed for use in those aged 18 years old and upwards)	✓	~
/	Trimbow [®] NEXThaler [®] 88/5/9mcg(Beclometasone + formoterol + glycopyrronium) (DPI) licensed for use in those aged 18 years old and upwards)	✓	1
	Trimbow [®] 87/5/9mcg(Beclometasone + formoterol + glycopyrronium) (MDI) (licensed for use in those aged 18 years old and upwards)	✓	✓
	Trixeo Aerosphere [®] (Budesonide + formoterol + glycopyrronium) (MDI) (licensed for use in those aged 18 years old and upwards)	✓	✓
Imm	unosuppresants – Monoclonal Antibodies		
	Mepolizumab (Nucala [®]) (1 st line)		✓
	Benralizumab (Fasenra®) (2 nd line)		✓
	Omalizumab (Xolair®)		1
	Dupilumab (Dupixent [®])		1
	Tezepelumab (Tezspire [®])		1
presc	nent: Monoclonal antibodies are restricted to use by clinicians responsible for adurities in line with SMC restrictions.	ults with severe	asthma. To be
Loui	Montelukast	√	1
Comi granu	nent: For patients with swallowing problems it is more cost-effective to use chewa	able tablets rath	er than
Xant	hines		
	Aminophylline Injection		✓
	Theophylline tablets (Uniphyllin Continus®)	✓	1
Peak	flow meters		
	Easy Peak Flow Meter (Low range, standard range)	1	 ✓
Inha	lermSpacers		
	Easychamber [®] Spacer +/-mask	✓	 ✓
Com childr	nent : Spacer + MDI is recommended in preference to dry powder or breath actuation	ted inhalers in y	vounger

Key \checkmark Initiate and continue \oplus Continue where appropriate.

Spacers should be replaced at least every year, especially if the spacer is used on a daily basis. May need to be replaced sooner in some individuals.

2. Allergic Conditions	Primary Care	Acute/ Specialist Services
Antihistamines – Non-sedating		
Cetirizine (1 st line)	✓	✓
Loratadine (1 st line)	✓	✓
Fexofenadine (2 nd line)	✓	✓
Antihistamines – Sedating		
Chlorphenamine	✓	✓
Promethazine	1	✓
2.1 Angiodema		
Treatments for angiodema are available via tertiary centres		
3. Conditions Affecting Sputum Viscosity	Primary Care	Acute/ Specialist Services
Mucolytics		
Mucolytics Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above)	4	✓
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18	✓ ✓	✓ ✓ ✓
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above)		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years)		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years) 3.1 Cystic Fibrosis		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years) 3.1 Cystic Fibrosis Treatments for cystic fibrosis are available via a tertiary centre in NHS Lothian		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years) 3.1 Cystic Fibrosis Treatments for cystic fibrosis are available via a tertiary centre in NHS Lothian 4. Cough and Congestion		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years) 3.1 Cystic Fibrosis Treatments for cystic fibrosis are available via a tertiary centre in NHS Lothian 4. Cough and Congestion No formulary choices		
Acetylcysteine effervescent tablets (Acepiro®) (1 st line in patients aged 18 years and above) Carbocisteine (1 st line in patients aged 2 - 18 years) 3.1 Cystic Fibrosis Treatments for cystic fibrosis are available via a tertiary centre in NHS Lothian 4. Cough and Congestion No formulary choices 5. Idiopathic Pulmonary Fibrosis		✓ ✓

6. Respiratory depression, respiratory distress syndrome and apnoea	Primary Care	Acute/ Specialist Services
---	-----------------	----------------------------------

Key \checkmark Initiate and continue \oplus Continue where appropriate.

Respiratory stimulants

Doxapram hydrochloride

Key ✓ Initiate and continue + Continue where appropriate. Forth Valley Formulary Reviewed October 22, Last amended November 2024 ✓